Redhill Biopharma Ltd. RDHL
0.50
(0.02)
(3.85%)
as of 25 Sep
- Market cap
- $3.2M
- P/E
- 0.0×
Follow RDHL
| Older periods | Mar '23 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
26.36 | 19.31 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(174.52) | (33.20) | — | — | |
P/B ratio |
619.94 | 170.01 | — | — | |
Price to Tangible BV |
0.00 | 0.00 | — | — | |
EV/Sales |
25.90 | 18.86 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(37.97) | (17.28) | — | — | |
EV/FCF |
(14.24) | (6.63) | — | — | |
Quick Ratio |
0.73 | 0.68 | 0.42 | 0.38 | |
Current Ratio |
0.96 | 0.96 | 0.74 | 0.56 | |
Net Debt/EBITDA |
2.29 | 1.95 | 0.00 | 0.00 | |
Debt/Assets |
11.89% | 6.52% | 0.00% | 0.00% | |
Debt/Equity |
3.49 | 0.66 | 0.00 | 0.00 | |
Asset Turnover |
0.42 | 0.30 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.14) | (23.62) | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.02) | |
Interest Coverage |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
30.12% | 69.44% | — | — | |
Selling, General and Administrative Expense of Revenue |
303.06% | 386.15% | — | — | |
Intangible Assets out of Total Assets |
0.10 | 0.16 | 0.25 | 0.30 | |
Share Based Compensation of Revenue |
4.04% | 47.81% | 0.00% | 0.00% | |
Graham Net Nets |
(0.01) | (0.01) | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(793.01%) | (2,035.56%) | — | — | |
Free Cash Flow Yield |
(6.90%) | (14.73%) | — | — | |
Revenue per Share |
0.29 | 0.09 | — | — | |
Operating CF per Share |
(0.59) | (0.90) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.59) | (0.90) | 0.00 | 0.00 | |
Cash per Share |
2.36 | 0.82 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.16 | 0.18 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
0.16 | 0.18 | 0.00 | 0.00 | |
Free Cash Flow |
(7.12) | (17.78) | (6.19) | (5.02) | |
Working Capital |
(1.92) | (1.14) | (5.53) | (9.73) | |
Capital Expenditures |
— | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
(10.31) | (4.52) | (6.26) | (10.23) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
1,395.98% | 42.37% | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
16.39 | 18.33 | 18.49 | 19.94 | |
Average Payables |
5.04 | 3.74 | 3.35 | 2.53 | |
Average Inventory |
10.07 | 8.33 | 8.19 | 7.09 | |
Average Assets |
112.94 | 101.50 | 89.61 | 88.62 | |
Average Common Equity |
(1.62) | (4.23) | (22.98) | (26.41) |
Columns are period end dates